File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.2174/187152012803529736
- Scopus: eid_2-s2.0-84872224518
- PMID: 22583425
- WOS: WOS:000310055000010
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Anti-cancer effects of curcumin on head and neck cancers
Title | Anti-cancer effects of curcumin on head and neck cancers |
---|---|
Authors | |
Keywords | Chemotherapeutic agent Curcumin Epigenetics regulation Head and neck cancer Matrix Metalloproteinases |
Issue Date | 2012 |
Publisher | Bentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cmcaca |
Citation | Anti-Cancer Agents in Medicinal Chemistry, 2012, v. 12 n. 9, p. 1110-1116 How to Cite? |
Abstract | Head and neck cancer is the sixth large type of cancer in the world. The treatment regimens for head and neck cancer encompass surgery, radiotherapy and chemotherapy. However, all current treatment regimens for head and neck cancer have adverse effects. Therefore, continuing investigations have been undertaken to seek less toxic therapies to reduce treatment morbidity for head and neck cancer. Substantial evidence has demonstrated that curcumin inhibited proliferation, migration, invasion and metastasis and induced apoptosis via modulating multiple signaling pathways in head and neck cancer. Curcumin also suppressed the growth of xenograft derived from head and neck cancer in vivo in animal models. This review summarizes the evidence demonstrating potential use of curcumin as a single chemotherapeutic agent or in combination with other chemotherapeutic agents and radiation to minimize their toxicity in head and neck cancer. Although curcumin has been shown to be safe at doses of 8 g/d in both phase I and phase II clinical trials, its bioavailability is poor. Overcoming the poor bioavailability of curcumin in the near future would facilitate its clinical use. |
Persistent Identifier | http://hdl.handle.net/10722/152867 |
ISSN | 2023 Impact Factor: 2.6 2023 SCImago Journal Rankings: 0.503 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gao, W | en_US |
dc.contributor.author | Chan, JYW | en_US |
dc.contributor.author | Wei, WI | en_US |
dc.contributor.author | Wong, TS | en_US |
dc.date.accessioned | 2012-07-16T09:51:02Z | - |
dc.date.available | 2012-07-16T09:51:02Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | Anti-Cancer Agents in Medicinal Chemistry, 2012, v. 12 n. 9, p. 1110-1116 | en_US |
dc.identifier.issn | 1871-5206 | - |
dc.identifier.uri | http://hdl.handle.net/10722/152867 | - |
dc.description.abstract | Head and neck cancer is the sixth large type of cancer in the world. The treatment regimens for head and neck cancer encompass surgery, radiotherapy and chemotherapy. However, all current treatment regimens for head and neck cancer have adverse effects. Therefore, continuing investigations have been undertaken to seek less toxic therapies to reduce treatment morbidity for head and neck cancer. Substantial evidence has demonstrated that curcumin inhibited proliferation, migration, invasion and metastasis and induced apoptosis via modulating multiple signaling pathways in head and neck cancer. Curcumin also suppressed the growth of xenograft derived from head and neck cancer in vivo in animal models. This review summarizes the evidence demonstrating potential use of curcumin as a single chemotherapeutic agent or in combination with other chemotherapeutic agents and radiation to minimize their toxicity in head and neck cancer. Although curcumin has been shown to be safe at doses of 8 g/d in both phase I and phase II clinical trials, its bioavailability is poor. Overcoming the poor bioavailability of curcumin in the near future would facilitate its clinical use. | - |
dc.language | eng | en_US |
dc.publisher | Bentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cmcaca | - |
dc.relation.ispartof | Anti-Cancer Agents in Medicinal Chemistry | en_US |
dc.subject | Chemotherapeutic agent | - |
dc.subject | Curcumin | - |
dc.subject | Epigenetics regulation | - |
dc.subject | Head and neck cancer | - |
dc.subject | Matrix Metalloproteinases | - |
dc.title | Anti-cancer effects of curcumin on head and neck cancers | en_US |
dc.type | Article | en_US |
dc.identifier.email | Gao, W: weigao@graduate.hku.hk | en_US |
dc.identifier.email | Chan, JYW: jywchan1@hku.hk | en_US |
dc.identifier.email | Wei, WI: hrmswwi@hku.hk | en_US |
dc.identifier.email | Wong, TS: wongtsa@hkucc.hku.hk | en_US |
dc.identifier.authority | Chan, YW=rp01314 | en_US |
dc.identifier.authority | Wei, WI=rp00323 | en_US |
dc.identifier.authority | Wong, STS=rp00478 | en_US |
dc.identifier.doi | 10.2174/187152012803529736 | - |
dc.identifier.pmid | 22583425 | - |
dc.identifier.scopus | eid_2-s2.0-84872224518 | - |
dc.identifier.hkuros | 200710 | en_US |
dc.identifier.volume | 12 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | 1110 | - |
dc.identifier.epage | 1116 | - |
dc.identifier.isi | WOS:000310055000010 | - |
dc.publisher.place | Netherlands | - |
dc.identifier.issnl | 1871-5206 | - |